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Abstract 
Background: Although the prognostic impact of body mass index (BMI) in patients with non‑metastatic naso‑
pharyngeal carcinoma (NPC) had been extensively studied, its effect among metastatic NPC patients remains 
unknown. The purpose of this study was to evaluate the prognostic effect of BMI in patients with metastatic NPC.
Methods: We retrospectively studied 819 patients who were diagnosed with distant metastasis from NPC and 
received treatment between 1998 and 2007. The patients were divided into three subgroups according to the 
World Health Organization classifications for Asian populations: underweight (BMI <18.5 kg/m2), normal weight (BMI 
18.5–22.9 kg/m2), and overweight/obese (BMI ≥23.0 kg/m2). The associations of BMI with overall survival (OS) and 
progression‑free survival (PFS) were determined by Cox regression analysis.
Results: Of the 819 patients, 168 (20.5%) were underweight, 431 (52.6%) were normal weight, and 220 (26.9%) 
were overweight/obese. Multivariate analysis adjusted for covariates showed that overweight/obese patients had 
a longer OS than underweight patients [hazard ratio (HR), 0.64; 95% confidence interval (CI), 0.49–0.84] and normal 
weight patients (HR, 0.72; 95% CI, 0.57–0.90); no significant difference in PFS was observed among these three groups 
(P = 0.407). Moreover, in stratified analysis, no statistically significant differences in the effect of overweight/obese 
status among different subgroups were observed.
Conclusion: For patients with metastatic NPC, overweight/obese status was associated with longer OS but not 
longer PFS compared with underweight or normal weight status.
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Background
Nasopharyngeal carcinoma (NPC) is an endemic head 
and neck epithelial malignancy, with the highest inci-
dence rate in Southeast Asia [1–3]. Although improve-
ments in radiation techniques and chemotherapy 
regimens have led to more effective treatments for NPC, 
15%–42% of patients still have treatment failures due to 
distant metastases [4–7]. Once metastasis is diagnosed, 
the prognosis of patients who are receiving palliative 
chemotherapy is very poor [8, 9]. Identifying prognostic 
factors for these patients may lead to the development of 
new clinical interventions to improve survival.
Body mass index (BMI) is a simple weight-for-height 
calculation that is commonly used to evaluate the nutri-
tional status in adults. Approximately 10% of patients 
with non-metastatic NPC are underweight at diagno-
sis; in terms of probability of recurrence, metastasis, 
and overall mortality, they have worse outcomes than 
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non-underweight patients [10, 11]. On the other hand, 
higher BMI seems to be associated with favorable prog-
nosis. In a recent published study of NPC patients, Shen 
et al. [11] found that the hazard ratio (HR) for death was 
0.66 [95% confidence interval (CI) 0.48–0.90] for over-
weight patients and 0.47 (95% CI 0.23–0.97) for obese 
patients compared with the baseline of normal weight or 
underweight patients. Although many studies have been 
conducted in patients with non-metastatic NPC, none 
has specifically evaluated the prognostic effect of BMI 
in patients with metastatic NPC. Long-term palliative 
chemotherapy can greatly impair the nutritional status of 
patients with metastatic NPC; therefore, understanding 
the prognostic effect of BMI may lead to better treatment 
planning.
In the present study, we investigated the prognos-
tic effects of BMI in patients with metastatic NPC who 
received systemic chemotherapy. Our previous study 
showed that NPC patients with different metastatic sites 
and different numbers of lesions appeared to be a very 
heterogeneous group in terms of survival [12]. Thus, we 
additionally performed a subgroup analysis to test the 
consistency of the effect of BMI.
Patients and methods
Patients
We reviewed the medical records of 1005 NPC patients 
with distant metastasis who were treated at Sun Yat-sen 
University Cancer Center between January 1998 and 
December 2007. The inclusion criteria included (1) histo-
logical or radiological confirmation of distant metastatic 
lesion(s); (2) Eastern Cooperative Oncology Group per-
formance status of grade 2 or lower; and (3) received at 
least one cycle of cisplatin-based chemotherapy as first-
line treatment. Exclusion criteria were either of the fol-
lowing: (1) Missing weight measurement at baseline and 
(2) younger than 18 years. The Hospital Ethics Commit-
tee of Sun Yat-sen University Cancer Center approved 
this study.
Definition
Primary diseases were staged according to the Union of 
International Cancer Control (UICC) staging system 
(6th edition) [13]. To define whether patients presented 
with distant metastasis when first diagnosed with NPC, 
metastasis onset was categorized as synchronous or 
metachronous. The metastatic site, number of metastatic 
organs, and number of metastases referred to the extent 
of disease at the time of diagnosis.
Patients’ baseline body weight was measured within 
14  days of the start of treatment after metastasis was 
diagnosed. BMI (kg/m2) was categorized according to the 
World Health Organization recommendations for Asian 
populations [14]. Because the number of obese patients 
was relatively few (20 patients), we merged overweight 
and obese patients and obtained three BMI subgroups: 
underweight (<18.5 kg/m2), normal weight (18.5–22.9 kg/
m2), and overweight/obese (≥23.0 kg/m2).
Treatment
Most patients who presented with synchronous metas-
tasis at initial NPC diagnosis received a cisplatin plus 
5-fluorouracil (5-FU) chemotherapy regimen (known as 
the PF regimen) before concurrent chemoradiotherapy. 
The concurrent chemotherapy regimen was either 5-FU 
plus cisplatin or cisplatin alone. The 5-FU plus cispl-
atin regimen was 70–100  mg/m2 of cisplatin on day 1 
plus 500–750 mg/m2 of 5-FU from day 2 to day 5 every 
3–4  weeks, for 2–3 cycles; the cisplatin regimen was 
30–40  mg/m2 of cisplatin every week, for 4–6 cycles. 
For patients who had metachronous metastasis after pri-
mary treatment, the first-line regimen was almost exclu-
sively platinum-based—cisplatin in combination with 
4–6 cycles of one or two of the following drugs: 5-FU, 
paclitaxel, gemcitabine, and bleomycin. The patients 
with progression underwent more than one-line chemo-
therapy regimen. Treatment discontinuation occurred at 
patient request or for unacceptable drug toxicity. Local 
therapies such as surgery, radiotherapy, interventional 
embolization, and radiofrequency ablation were available 
for those patients who still had metastatic lesions after 
chemotherapy.
Follow‑up and endpoints
During palliative chemotherapy, patients were evalu-
ated by computed tomography or magnetic resonance 
imaging for response every two cycles and then every 
3  months until death or the last follow-up (June 30, 
2014). The primary outcomes were overall survival (OS) 
and progression-free survival (PFS). OS was defined as 
time from the diagnosis of distant metastasis to death 
by any cause. PFS was defined as time from the diagno-
sis of distant metastasis to tumor progression or death by 
cancer.
Statistical analyses
The Pearson χ2 test was used to compare the categori-
cal variables among groups respectively. OS and PFS 
rates were estimated using the Kaplan–Meier method 
and compared among the BMI subgroups by the log-
rank test. The multiple-adjusted Cox model was used 
to determine the effect of BMI on survival; covariates 
included age, sex, UICC T category, UICC N category, 
metastatic onset, lung metastasis (absent versus present), 
liver metastasis (absent versus present), bone metasta-
sis (absent versus present), single lesion (no versus yes), 
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number of involved sites, and treatment modality. To 
test the consistency of the favorable effect associated 
with overweight/obese status, a subgroup analysis using 
the multiple-adjusted Cox model was further conducted, 
with all the covariates, except for stratification factor, 
included. The Cox regression model, including two main 
effect parameters and their interaction effect parameters, 
was used to test the interaction effect between BMI and 
the other covariates. P values less than 0.05 were con-
sidered statistically significant. Statistical analyses were 




A total of 819 patients who met the inclusion criteria 
were included in this study. Table  1 shows the baseline 
characteristics of the 819 patients with metastatic NPC. 
The median age was 45  years (range 18–78  years). Of 
these patients, 772 (94.3%) had undifferentiated non-
keratinizing carcinoma, 31 (3.8%) had differentiated 
non-keratinizing carcinoma, and 16 (1.9%) had other 
types; 272 (33.2%) had synchronous metastasis, and 547 
(66.8%) had metachronous metastasis. Two hundred 
seventy-four (33.5%) patients had more than one meta-
static site.  All patients in either the synchronous or the 
metachronous group received at least one cycle of plat-
inum-based chemotherapy (median, four cycles). Local 
therapy for metastases was administered to 212 (25.9%) 
patients. The median follow-up time for patients was 
18 months (range 1–120 months).
For all patients, the median BMI was 21.2 kg/m2. A total 
of 168 patients (20.5%) were underweight, 431 (52.6%) 
were normal weight, and 220 (26.9%) were overweight/
obese. The proportion of overweight/obese was higher in 
patients who had synchronous metastasis than in those 
who had metachronous metastasis and were higher in 
patients aged ≥45 years than in patients aged <45 years. 
Additionally, the proportion of underweight was higher 
in patients who had bone metastasis or multiple lesions 
than in patients who did not have. No significant differ-
ences were observed in sex, UICC T category, UICC N 
category, lung metastasis, liver metastasis, number of 
involved sites, and treatment modality across the BMI 
subgroups (Table 1).
BMI and survival
For the 819 patients included in this analysis, 653 (79.7%) 
progressions and 498 (60.8%) deaths were recorded. The 
1-, 3-, and 5-year OS rates for the whole patient popu-
lation were 81.4%, 33.7% and 16.7%, respectively; the 1-, 
3-, and 5-year PFS rates were 47.6%, 16.6% and 7.1%, 
respectively.
In univariate analysis, overweight/obese patients had 
a significantly higher 5-year OS rate than underweight 
patients (25.9% vs. 12.3%, P < 0.001) and normal weight 
patients (25.9% vs. 14.6%, P  =  0.008), whereas no sig-
nificant difference was observed between underweight 
and normal weight patients (P = 0.112; Fig. 1a). In con-
trast, overweight/obese patients had significantly higher 
5-year PFS rates than underweight patients (11.9% vs. 
3.5%, P  =  0.042), whereas no significant differences 
were observed between normal weight and overweight/
obese patients (P = 0.333) or between normal weight and 
underweight patients (P = 0.141) (Fig. 1b). Other factors 
influencing OS and PFS are listed in Tables 2 and 3.
Multiple-adjusted Cox model was used in multivari-
ate analysis with covariates including age, sex, UICC 
T category, UICC N category, metastatic onset, lung 
metastasis, liver metastasis, bone metastasis, solitary 
lesion, number of involved sites, and treatment modal-
ity. Collinearity for all the adjusting variables was tested, 
resulting in variance inflation factors (1.02–2.62) and tol-
erances (0.44–0.98) within acceptable regression limits. 
Overweight/obese patients had a significantly lower risk 
of death compared with underweight patients (HR 0.62; 
95% CI 0.48–0.81; Table  2) and normal weight patients 
(HR 0.72; 95% CI 0.57–0.90), whereas no significant dif-
ference was observed in OS between normal weight and 
underweight patients (HR 0.84; 95% CI 0.67–1.04). The 
other significant prognostic factors for OS included age, 
UICC N category, metastasis onset, liver metastasis, and 
treatment modality. In multiple-adjusted analysis for 
PFS, BMI was not significant; the significant prognostic 
factors included UICC N category, liver metastasis, bone 
metastasis, and treatment modality (Table 3).
To examine the consistency of the effect of BMI in 
patients with metastatic NPC, we conducted further 
stratified analysis using the multiple-adjusted model 
(Table  4). No statistically significant differences were 
observed in the effects of overweight/obese status on 
other explanatory variables, but the effect seemed more 
pronounced in NPC patients with bone metastasis and 
in patients receiving chemotherapy only. The magnitude 
of favorable effect of overweight/obese status was similar 
across the age, sex, UICC T category, UICC N category, 
and metastasis onset categories.
Discussion
In the present study, we found that, in patients with met-
astatic NPC, BMI was an independent prognostic factor 
for OS but not for PFS. Patients who were overweight/
obese had a significantly lower risk of death than under-
weight and normal weight patients; this effect was more 
pronounced in patients with bone metastasis and in 
those who received chemotherapy only.
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Several studies reported on the prognostic effect 
of BMI in patients with NPC [6, 10, 15], and there is 
increasing awareness that this effect may vary in differ-
ent subgroups. Huang et al. [16] retrospectively analyzed 
the data of 400 patients with stage III or stage IVa NPC 
who received chemoradiotherapy. They found that, com-
pared with normal weight patients, overweight patients 
had a more favorable OS (HR 0.57; 95% CI 0.39–0.85) 
and distant failure-free survival (HR 0.61; 95% CI 0.40–
0.92) [16]. This finding suggests that nutritional status 
might also play a critical role in advanced-stage or even 
end-stage NPC patients. A recent study by Pan et al. [17] 
evaluated the prognostic effect of anatomic features of 
metastases in patients with metastatic NPC. They showed 
that, in the synchronous metastatic group, underweight 
status was an unfavorable prognostic factor, whereas in 
the metachronous group, its effect failed to reach signifi-
cance [17]. However, in their study, covariates associated 
with the treatment modality were not included in the 
analysis, and BMI level was simply dichotomized (<18.5   
vs. ≥18.5 kg/m2), which impeded further interpretation. 
In our study, we observed a markedly higher OS rate (but 
Table 1 Baseline characteristics by BMI level of patients with metastatic nasopharyngeal carcinoma (NPC)
All values are presented as the number of cases followed by percentage in the parentheses
BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy
* P values were computed excluding patients without information in the corresponding variable
Variable All Underweight Normal weight Overweight/obese P value*
Total 819 168 431 220
Age (years) 0.043
 <45 419 (51.2) 97 (57.7) 223 (51.7) 99 (45.0)
 ≥45 400 (48.8) 71 (42.3) 208 (48.3) 121 (55.0)
Sex 0.688
 Men 681 (83.2) 139 (82.7) 355 (82.4) 187 (85.0)
 Women 138 (16.8) 29 (17.3) 76 (17.6) 33 (15.0)
UICC T category 0.504
 T1–2 369 (45.1) 76 (45.2) 201 (46.6) 92 (41.8)
 T3–4 450 (54.9) 92 (54.8) 230 (53.4) 128 (58.2)
UICC N category 0.221
 N0–1 417 (50.9) 89 (53.0) 227 (52.7) 101 (45.9)
 N2–3 402 (49.1) 79 (47.0) 204 (47.3) 119 (54.1)
Metastasis onset <0.001
 Synchronous 272 (33.2) 42 (25.0) 135 (31.3) 95 (43.2)
 Metachronous 547 (66.8) 126 (75.0) 296 (68.7) 125 (56.8)
Lung metastasis 0.709
 Absent 469 (57.3) 96 (57.1) 242 (56.1) 131 (59.5)
 Present 350 (42.7) 72 (42.9) 189 (43.9) 89 (40.5)
Liver metastasis 0.201
 Absent 574 (70.1) 118 (70.2) 292 (67.7) 164 (74.5)
 Present 245 (29.9) 50 (29.8) 139 (32.3) 56 (25.5)
Bone metastasis 0.032
 Absent 382 (46.6) 67 (39.9) 219 (50.8) 96 (43.6)
 Present 437 (53.4) 101 (60.1) 212 (49.2) 124 (56.4)
Solitary lesion 0.010
 No 701 (85.6) 155 (92.3) 356 (82.6) 190 (86.4)
 Yes 118 (14.4) 13 (7.7) 75 (17.4) 30 (13.6)
Number of involved sites 0.592
 One 545 (66.5) 107 (63.7) 287 (66.6) 151 (68.6)
 Two or more 274 (33.5) 61 (36.3) 144 (33.4) 69 (31.4)
Treatment modality 0.322
 CT 607 (74.1) 132 (78.6) 313 (72.6) 162 (73.6)
 CT + LT 212 (25.9) 36 (21.4) 118 (27.4) 58 (26.4)
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not a higher PFS rate) in overweight/obese patients com-
pared with underweight or normal weight patients. Since 
we observed a differential distribution for age, metastasis 
onset, bone metastasis, and the number of lesions in the 
BMI subgroups, we conducted a multiple-adjusted anal-
ysis and found that the BMI level was still significant in 
predicting OS, with its effect consistent in both the syn-
chronous metastasis and the metachronous metastasis 
groups. In aggregate, these results suggest that BMI level 
is an important prognostic factor in patients with meta-
static NPC.
The reason for the prognostic effect of BMI in patients 
with metastatic NPC may mainly involve malnutrition. 
Underweight head and neck cancer patients are more 
susceptible to malnutrition and even cachexia—both 
known to be associated with compromised immunity 
[18, 19], reduced tolerance to oncologic therapies [20, 
21], and poor treatment outcome [22–25]—than patients 
with higher BMI. By contrast, patients who are over-
weight or obese may tolerate therapy better and therefore 
may have better outcomes. In addition, comorbidities 
like diabetes, chronic obstructive pulmonary disease, 
and cardiovascular diseases could worsen the prognosis 
of NPC patients; these comorbidities might also lead to 
low BMI [2, 26]. A recent study of 1001 newly diagnosed 
NPC patients showed that, before radiation treatment, 
15.5% of elderly patients (>70  years old) presented with 
moderate to severe comorbidities (Adult Comorbid-
ity Evaluation-27 score >2); these patients had lower OS 
rate (HR 2.63; 95% CI 1.45–4.76) than patients who had 
no comorbidities or mild comorbidities. However, in our 
population, the proportion of elderly patients was rather 
small (16 patients; 1.9%); thus, this may not be an impor-
tant consideration [27].
We found that pre-treatment BMI level was indepen-
dently associated with OS in patients with metastatic 
NPC, but it is interesting that BMI did not have an 
effect on PFS. Currently, no curative therapy is avail-
able for metastatic NPC. One plausible explanation 
for this may be that, for patients with metastatic NPC, 
being overweight or obese does not guarantee that any 
given oncologic therapy will have improved efficacy; 
being overweight or obese may, however, associate with 
a higher tolerance to continuous treatment, resulting in 
superior long-term benefits [9, 28]. Moreover, this may 
be partly supported by our preliminary data that the 
overweight/obese group received more cycles of pal-
liative chemotherapy after metastasis diagnosis than the 
other two groups (overweight/obese: median, five cycles; 
normal weight: median, three cycles; underweight: 
median, four cycles).
Our study showed the clinical course of a large cohort 
of patients with metastatic NPC. OS varied among the 
patients (range 1–120  months), and the 5-year OS rates 
after metastasis for overweight/obese, normal weight, and 
underweight patients were 25.9%, 14.6% and 12.3%, respec-
tively. These results indicate that long-term survival is 
possible for some patients and that more aggressive multi-
modality treatment should be encouraged for patients with 
high baseline BMI. Interestingly, the unfavorable prognos-
tic effect of underweight status in patients who received 
chemotherapy combined with local therapy was absent; 
this suggests that patients with localized metastatic lesions 
who receive local therapy might overcome the negative 
Fig. 1 Overall survival (OS) and progression‑free survival (PFS) for metastatic nasopharyngeal carcinoma (NPC) patients by body mass index (BMI) 
levels. Overweight/obese patients had significantly higher OS (a) and PFS (b) rates than underweight patients, whereas no significant differences 
were observed in OS and PFS between normal weight and underweight patients. UW underweight, NW normal weight, OW overweight/obese
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effect of low baseline BMI. In addition, since patients with 
higher BMI levels may be more tolerant to intensive treat-
ment, and since a higher dosage or denser interval of chem-
oradiotherapy could potentially be beneficial, future clinical 
trials that investigate the optimal dosage and interval of 
chemotherapy are important and warranted.
Our results suggest that, for patients with metastatic 
NPC, certain interventions that target underweight status 
or malnutrition might be beneficial. For the past decade, 
ample evidence has shown that, for patients with head and 
neck cancer, adequate nutrition support before and dur-
ing treatment can decrease the severity of adverse effects, 
minimize weight loss, and improve outcomes [29, 30]. 
Studies have suggested that patients with head and neck 
cancer who have a BMI less than 20 kg/m2 should receive 
further assessment, intensive counselling, and nutrition 
support [31–33]. However, owing to a lack of high-quality 
studies, recent reviews were not able to provide evidence 
for or against a role of nutrition support in head neck can-
cer patients [31, 34, 35]. Additionally, no study has spe-
cifically focused on the effect of nutrition intervention on 
patients with NPC. Therefore, multicenter randomized 
controlled trials and well-designed observation studies 
that examine nutrition intervention are needed.
This study had several limitations. First, it was a ret-
rospective study. Second, BMI was measured only at the 
diagnosis of metastasis, and further changes were not 
considered owing to the difficulty of assessing changes 
influenced by adverse effects of different chemotherapy/
Table 2 Univariate and multivariate analyses of covariates 
associated with overall survival in patients with metastatic 
NPC
UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; 
BMI body mass index; HR hazard ratio; CI confidence interval
a P value with respect to the significance of differential prognosis between BMI 
subgroups
Variable Univariate Multivariate
HR (95 % CI) P HR (95 % CI) P
Age (<45 years vs. 
≥45 years)
1.23 (1.03–1.46) 0.023 1.28 (1.07–1.53) 0.007
Sex (men vs. 
women)
1.02 (0.81–1.29) 0.870 1.01 (0.79–1.27) 0.958
UICC T category 
(T1–2 vs. T3–4)
0.91 (0.77–1.09) 0.310 0.94 (0.78–1.12) 0.480
UICC N category 
(N0–1 vs. N2–3)




1.13 (0.94–1.37) 0.199 1.24 (1.01–1.53) 0.039
Solitary lesion (no 
vs. yes)












1.20 (1.01–1.44) 0.039 1.31 (1.00–1.73) 0.055
Number of involved 
sites (one vs. two 
or more)
1.39 (1.16–1.67) <0.001 0.97 (0.72–1.29) 0.814
Treatment modality 
(CT vs. CT + LT)
0.67 (0.55–0.82) <0.001 0.68 (0.55–0.85) <0.001
BMI 0.001a 0.003a
 Underweight vs. 
normal weight
0.84 (0.67–1.04) 0.112 0.90 (0.72–1.12) 0.330
 Underweight vs. 
overweight/
obese
0.62 (0.48–0.81) <0.001 0.64 (0.49–0.84) 0.001
Table 3 Univariate and  multivariate analyses of  covari-
ates associated with  progression-free survival in  patients 
with metastatic NPC
UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; 
BMI body mass index; HR hazard ratio; CI confidence interval
a P value with respect to the significance of differential prognosis between BMI 
subgroups
Variable Univariate Multivariate
HR (95 % CI) P HR (95 % CI) P
Age (<45 years vs. 
≥45 years)
1.01 (0.87–1.18) 0.863 1.03 
(0.88–1.20)
0.760
Sex (men vs. women) 1.04 (0.85–1.27) 0.730 1.04 
(0.84–1.27)
0.745
UICC T category 
(T1–2 vs. T3–4)
0.92 (0.79–1.07) 0.289 0.92 
(0.78–1.07)
0.274
UICC N category 
(N0–1 vs. N2–3)






1.04 (0.88–1.23) 0.647 1.17 
(0.98–1.39)
0.091
Solitary lesion (no 
vs. yes)















1.27 (1.09–1.48) 0.003 1.33 
(1.05–1.68)
0.019
Number of involved 
sites (one vs. two or 
more)




(CT vs. CT + LT)




 Underweight vs. 
normal weight
0.87 (0.72–1.06) 0.141 0.91 
(0.75–1.11)
0.367
 Underweight vs. 
overweight/obese
0.80 (0.64–1.00) 0.042 0.86 
(0.68–1.08)
0.181
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local therapy. Finally, the applied modes of chemotherapy 
and local therapy varied, which might have a confound-
ing effect. For these reasons, our findings need to be vali-
dated in a multi-institutional prospective study.
Conclusions
This study showed that, for patients receiving palliative 
chemotherapy, overweight or obese at baseline was asso-
ciated with longer OS compared with underweight or 
normal weight. This association was similar across patient 
subgroups and seemed pronounced in patients with bone 
metastasis and in those who received chemotherapy only. 
These data emphasize the link between malnutrition and 
the survival of patients with metastatic NPC and suggest 
that nutritional intervention may be recommended for 
underweight and normal weight patients.
Abbreviations
NPC: nasopharyngeal carcinoma; BMI: body mass index; PFS: progression‑free 
survival; OS: overall survival; HR: hazard ratio; CI: confidence interval.
Table 4 Multiple-adjusted HRs for OS by baseline BMI level, stratified by covariates
OS overall survival; BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; HR hazard ratio; CI confidence interval
a Adjusted for age, sex, UICC T category, UICC N category, onset of metastasis, solitary lesion, lung metastasis, liver metastasis, bone metastasis, number of involved 
sites, and treatment modality, excluding stratification covariate
b P for interaction






 <45 419 1.0 1.01 (0.74–1.38) 0.74 (0.50–1.09)
 ≥45 400 1.0 0.76 (0.55–1.06) 0.54 (0.37–0.79)
Sex 0.680
 Men 681 1.0 0.82 (0.64–1.04) 0.59 (0.44–0.79)
 Women 138 1.0 1.29 (0.67–2.45) 0.93 (0.45–1.94)
UICC T category 0.471
 T1–2 369 1.0 0.84 (0.60–1.17) 0.78 (0.52–1.17)
 T3–4 450 1.0 0.88 (0.65–1.19) 0.49 (0.34–0.70)
UICC N category 0.501
 N0–1 417 1.0 0.83 (0.61–1.14) 0.55 (0.37–0.82)
 N2–3 402 1.0 0.86 (0.60–1.18) 0.67 (0.46–0.98)
Metastasis onset 0.551
 Synchronous 272 1.0 0.94 (0.60–1.49) 0.55 (0.33–0.90)
 Metachronous 547 1.0 0.80 (0.62–1.04) 0.67 (0.48–0.92)
Lung metastasis 0.761
 Absent 469 1.0 0.92 (0.69–1.24) 0.66 (0.46–0.95)
 Present 350 1.0 0.78 (0.54–1.12) 0.62 (0.40–0.94)
Liver metastasis 0.098
 Absent 574 1.0 0.70 (0.54–0.91) 0.45 (0.32–0.62)
 Present 245 1.0 1.39 (0.22–2.19) 1.46 (0.88–2.43)
Bone metastasis 0.051
 Absent 382 1.0 0.83 (0.58–1.18) 0.76 (0.50–1.14)
 Present 437 1.0 0.91 (0.68–1.23) 0.57 (0.39–0.82)
Solitary lesion 0.062
 No 701 1.0 0.90 (0.72–1.14) 0.60 (0.45–0.80)
 Yes 118 1.0 0.35 (0.14–0.86) 0.44 (0.17–1.13)
Number of involved sites 0.331
 One 545 1.0 0.72 (0.57–0.99) 0.53 (0.38–0.74)
 Two or more 274 1.0 1.11 (0.75–1.66) 0.84 (0.52–1.33)
Treatment modality 0.055
 CT 607 1.0 0.92 (0.71–1.19) 0.56 (0.41–0.77)
 CT + LT 212 1.0 0.74 (0.46–1.21) 0.89 (0.52–1.52)
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